(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.05%) $0.791
(0.86%) $85.73
-10.45% $ 0.0600
Live Chart Being Loaded With Signals
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial...
Stats | |
---|---|
Tagesvolumen | 54 400 |
Durchschnittsvolumen | 47 657 |
Marktkapitalisierung | 4.51M |
EPS | $-0.0281 ( Q2 | 2023-12-31 ) |
Nächstes Ertragsdatum | ( $0 ) 2024-08-14 |
Last Dividend | $0.186 ( 2023-12-08 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.750 (Sector) 0 (Industry) 0 |
ATR14 | $0 (0.00%) |
Invex Therapeutics Ltd Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Invex Therapeutics Ltd Finanzdaten
Annual | 2023 |
Umsatz: | $459 085 |
Bruttogewinn: | $459 085 (100.00 %) |
EPS: | $-0.100 |
FY | 2023 |
Umsatz: | $459 085 |
Bruttogewinn: | $459 085 (100.00 %) |
EPS: | $-0.100 |
FY | 2022 |
Umsatz: | $182 251 |
Bruttogewinn: | $182 251 (100.00 %) |
EPS: | $-0.0526 |
FY | 2021 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-0.0407 |
Financial Reports:
No articles found.
Invex Therapeutics Ltd Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0.186 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.186 | 2023-12-08 |
Last Dividend | $0.186 | 2023-12-08 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-18 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.186 | -- |
Avg. Dividend % Per Year | 11.07% | -- |
Score | 4.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.186 | 33.20% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
08 Dec 2023 | $0.186 | 30 Nov -0001 | 11 Dec 2023 | 18 Dec 2023 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
EZL.AX | Dividend Royal | 2024-02-02 | Semi-Annually | 24 | 11.64% | 8.24 |
GRR.AX | Dividend Royal | 2024-03-12 | Semi-Annually | 14 | 11.88% | 7.99 |
RKN.AX | Dividend Royal | 2023-08-31 | Annually | 22 | 15.73% | 7.24 |
TWR.AX | Dividend King | 2024-06-12 | Annually | 25 | 5.98% | 7.21 |
YAL.AX | Dividend Royal | 2024-03-12 | Annually | 7 | 12.76% | 7.18 |
SHM.AX | Dividend Royal | 2024-03-14 | Semi-Annually | 9 | 14.97% | 7.14 |
HZN.AX | Dividend Royal | 2024-04-18 | Semi-Annually | 4 | 18.99% | 7.06 |
BHP.AX | Dividend Royal | 2024-03-07 | Semi-Annually | 37 | 6.46% | 6.97 |
CDD.AX | Ex Dividend King | 2024-05-24 | Annually | 21 | 91.43% | 6.79 |
KSL.AX | Dividend Royal | 2024-03-05 | Semi-Annually | 9 | 9.58% | 6.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -10.40 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.881 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.674 | 1.500 | -8.60 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 6.38 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 6.38 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 6.25 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.142 | 2.00 | -0.0473 | -0.0946 | [0 - 30] |
freeCashFlowPerShareTTM | -0.142 | 2.00 | -0.0709 | -0.142 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.339 | 1.000 | 7.69 | 7.69 | [0.2 - 0.8] |
operatingProfitMarginTTM | -11.84 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.181 | 0.800 | -2.13 | -1.702 | [0.5 - 2] |
Total Score | -1.447 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.426 | 1.000 | -0.144 | 0 | [1 - 100] |
returnOnEquityTTM | -0.674 | 2.50 | -5.53 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.142 | 2.00 | -0.0473 | -0.142 | [0 - 30] |
dividendYielPercentageTTM | 278.06 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.142 | 2.00 | -0.0473 | -0.0946 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0170 | 1.500 | -3.45 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -9.39 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.550 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Invex Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.